13,798 Shares in Kenvue Inc. (NYSE:KVUE) Acquired by Coordinated Financial Services Inc.

Coordinated Financial Services Inc. acquired a new stake in Kenvue Inc. (NYSE:KVUE) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 13,798 shares of the company’s stock, valued at approximately $295,000.

Other hedge funds have also recently bought and sold shares of the company. Grove Bank & Trust boosted its position in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in Kenvue in the 4th quarter valued at $29,000. SRS Capital Advisors Inc. boosted its position in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after buying an additional 571 shares during the last quarter. Fortitude Family Office LLC boosted its position in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in Kenvue in the 3rd quarter valued at $35,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on KVUE. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. UBS Group cut their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Canaccord Genuity Group increased their price target on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup cut their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Finally, Piper Sandler increased their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and a consensus target price of $23.75.

Kenvue Stock Performance

KVUE opened at $23.46 on Friday. The business’s 50-day moving average price is $21.64 and its two-hundred day moving average price is $22.33. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a market capitalization of $44.83 billion, a price-to-earnings ratio of 44.25, a P/E/G ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.50%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio is 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.